Brief: Lucid Diagnostics Receives Notice Of Allowance For Key Patent Underlying Its Esoguard Esophageal DNA Test
15/10/2024 13:06
Oct 15 (Reuters) - Lucid Diagnostics Inc LUCD.O :
* LUCID DIAGNOSTICS RECEIVES NOTICE OF ALLOWANCE FOR KEY
PATENT
UNDERLYING ITS ESOGUARD ESOPHAGEAL DNA TEST
Source text for Eikon: ID:nPn3vgZZPa
Further company coverage: LUCD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PAVmed
See all newsBrief: Lucid Diagnostics Begins Receiving Medicare Reimbursement For Esoguard® And Closes $15 Million Financing
PAVmed Inc reports results for the quarter ended June 30 - Earnings Summary
PAVmed Inc expected to post a loss of 47 cents a share - Earnings Preview
NASDAQ RESUMED AT 11:36 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:21 AM